0001415889-24-020010.txt : 20240723 0001415889-24-020010.hdr.sgml : 20240723 20240723210514 ACCESSION NUMBER: 0001415889-24-020010 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20240722 FILED AS OF DATE: 20240723 DATE AS OF CHANGE: 20240723 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Moshkevich Solomon CENTRAL INDEX KEY: 0002010019 ORGANIZATION NAME: FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-37478 FILM NUMBER: 241135926 MAIL ADDRESS: STREET 1: C/O NATERA, INC. STREET 2: 13011 MCCALLEN PASS, BLDG A, SUITE 100 CITY: AUSTIN STATE: TX ZIP: 78753 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Natera, Inc. CENTRAL INDEX KEY: 0001604821 STANDARD INDUSTRIAL CLASSIFICATION: SERVICES-MEDICAL LABORATORIES [8071] ORGANIZATION NAME: 08 Industrial Applications and Services IRS NUMBER: 010894487 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 13011 MCCALLEN PASS STREET 2: BUILDING A SUITE 100 CITY: AUSTIN STATE: TX ZIP: 78753 BUSINESS PHONE: 650-249-9090 MAIL ADDRESS: STREET 1: 13011 MCCALLEN PASS STREET 2: BUILDING A SUITE 100 CITY: AUSTIN STATE: TX ZIP: 78753 4 1 form4-07232024_090711.xml X0508 4 2024-07-22 0001604821 Natera, Inc. NTRA 0002010019 Moshkevich Solomon C/O NATERA, INC. 13011 MCCALLEN PASS BUILDING A SUITE 100 AUSTIN TX 78753 false true false false PRESIDENT, CLINICALDIAGNOSTICS 1 Common Stock 2024-07-22 4 S 0 549 105.1597 D 113637 D The sale of shares was effected in order to satisfy tax withholding and remittance obligations in connection with the vesting of RSUs and made pursuant to a written instruction that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) under the Exchange Act contained in the Reporting Person's Stock Unit Agreements granted on January 22, 2021 and January 28, 2022. The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $104.9850 to $105.16 per share, inclusive. The holder undertakes to provide, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. /s/ Tami Chen, Attorney-in-Fact 2024-07-23